BRPI0908433A2 - pirrolo[2,3-d]piridinas e empregos destas como inibidores tirosina cinase - Google Patents
pirrolo[2,3-d]piridinas e empregos destas como inibidores tirosina cinaseInfo
- Publication number
- BRPI0908433A2 BRPI0908433A2 BRPI0908433A BRPI0908433A BRPI0908433A2 BR PI0908433 A2 BRPI0908433 A2 BR PI0908433A2 BR PI0908433 A BRPI0908433 A BR PI0908433A BR PI0908433 A BRPI0908433 A BR PI0908433A BR PI0908433 A2 BRPI0908433 A2 BR PI0908433A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyridines
- pyrrolo
- tyrosine kinase
- kinase inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08151137 | 2008-02-06 | ||
PCT/EP2009/051281 WO2009098236A1 (en) | 2008-02-06 | 2009-02-04 | Pyrrolo [2, 3-d] pyridines and use thereof as tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0908433A2 true BRPI0908433A2 (pt) | 2019-09-24 |
Family
ID=39739330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0908433A BRPI0908433A2 (pt) | 2008-02-06 | 2009-02-04 | pirrolo[2,3-d]piridinas e empregos destas como inibidores tirosina cinase |
Country Status (27)
Country | Link |
---|---|
US (1) | US8420657B2 (pt) |
EP (1) | EP2247591A1 (pt) |
JP (1) | JP5323095B2 (pt) |
KR (2) | KR101277823B1 (pt) |
CN (1) | CN101981036B (pt) |
AR (1) | AR070558A1 (pt) |
AU (1) | AU2009211338B2 (pt) |
BR (1) | BRPI0908433A2 (pt) |
CA (1) | CA2714177A1 (pt) |
CL (1) | CL2009000255A1 (pt) |
CO (1) | CO6321262A2 (pt) |
CR (1) | CR11614A (pt) |
DO (1) | DOP2010000242A (pt) |
EA (1) | EA017952B1 (pt) |
EC (1) | ECSP10010463A (pt) |
IL (1) | IL207224A0 (pt) |
MA (1) | MA32134B1 (pt) |
MX (1) | MX2010008719A (pt) |
NI (1) | NI201000137A (pt) |
NZ (1) | NZ587271A (pt) |
PA (1) | PA8815201A1 (pt) |
PE (1) | PE20091485A1 (pt) |
SM (1) | SMP201000104B (pt) |
TW (1) | TW200938202A (pt) |
UY (1) | UY31631A1 (pt) |
WO (1) | WO2009098236A1 (pt) |
ZA (1) | ZA201005338B (pt) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI398252B (zh) | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
US20110064671A1 (en) * | 2008-03-10 | 2011-03-17 | Cornell University | Modulation of blood brain barrier permeability |
US8426411B2 (en) * | 2008-06-10 | 2013-04-23 | Abbott Laboratories | Tricyclic compounds |
CA2734802C (en) | 2008-08-22 | 2016-05-31 | Novartis Ag | Pyrrolopyrimidine compounds as cdk inhibitors |
US8546377B2 (en) | 2009-04-23 | 2013-10-01 | Abbvie Inc. | Modulators of 5-HT receptors and methods of use thereof |
ES2568262T3 (es) * | 2009-04-23 | 2016-04-28 | Abbvie Inc. | Moduladores de receptores de 5-HT y sus métodos de uso |
US8518933B2 (en) * | 2009-04-23 | 2013-08-27 | Abbvie Inc. | Modulators of 5-HT receptors and methods of use thereof |
CN102666545B (zh) * | 2009-10-20 | 2016-04-06 | 塞尔卓姆有限公司 | 作为jak抑制剂的杂环吡唑并嘧啶类似物 |
US8791100B2 (en) | 2010-02-02 | 2014-07-29 | Novartis Ag | Aryl benzylamine compounds |
UY33226A (es) * | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
JP2013525392A (ja) | 2010-04-30 | 2013-06-20 | セルゾーム リミティッド | Jak阻害剤としてのピラゾール化合物 |
TW201204732A (en) | 2010-07-09 | 2012-02-01 | Leo Pharma As | Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof |
JP2013534233A (ja) * | 2010-08-20 | 2013-09-02 | セルゾーム リミティッド | 選択的jak阻害剤としてのヘテロシクリルピラゾロピリミジン類似体 |
EP2616538A4 (en) * | 2010-09-16 | 2014-03-05 | Univ Cornell | USE OF ADENOSINE RECEPTOR SIGNALS FOR MODULATING THE PERMEABILITY OF THE BLOOD-BRAIN BARRIER |
WO2012143320A1 (en) | 2011-04-18 | 2012-10-26 | Cellzome Limited | (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors |
EA030465B1 (ru) | 2011-07-01 | 2018-08-31 | Новартис Аг | Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака |
EP2760863A1 (en) * | 2011-09-20 | 2014-08-06 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors |
MX2014005927A (es) | 2011-11-15 | 2014-06-05 | Novartis Ag | Combinacion de un inhibidor de la fosfoinositida-3-cinasa y un modulador de la senda del transductor y activador de la señal de transcripcion 5 de la cinasa janus 2. |
CN102627646A (zh) * | 2012-03-19 | 2012-08-08 | 苏州四同医药科技有限公司 | 一种3-碘-5-溴-4,7-二氮杂吲哚的制备方法 |
CN102633802B (zh) * | 2012-04-11 | 2014-03-19 | 南京药石药物研发有限公司 | 一种合成2-氯-7H-吡咯并[2,3-d]嘧啶的中间体及其制法 |
US9670213B2 (en) * | 2012-05-14 | 2017-06-06 | East China University Of Science And Technology | Pteridine ketone derivative and applications thereof as EGFR, BLK, and FLT3 inhibitor |
CN103059030B (zh) * | 2012-12-28 | 2015-04-29 | 北京师范大学 | 一种具有粘着斑激酶抑制作用的嘧啶类化合物及其制备方法和应用 |
WO2014145576A2 (en) | 2013-03-15 | 2014-09-18 | Northwestern University | Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer |
CN106458914B (zh) * | 2014-03-28 | 2020-01-14 | 常州捷凯医药科技有限公司 | 作为axl抑制剂的杂环化合物 |
WO2015168269A1 (en) * | 2014-05-01 | 2015-11-05 | Novartis Ag | Compounds and compositions as toll-like receptor 7 agonists |
SG11201608299TA (en) | 2014-05-01 | 2016-11-29 | Novartis Ag | Compounds and compositions as toll-like receptor 7 agonists |
MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
AU2019245420A1 (en) | 2018-03-30 | 2020-11-12 | Incyte Corporation | Treatment of hidradenitis suppurativa using JAK inhibitors |
CN111484496B (zh) * | 2019-01-29 | 2022-11-29 | 江苏开元药业有限公司 | 2-氨基-吡咯并嘧啶和吡唑并嘧啶类化合物及其制备方法和用途 |
SG11202112362YA (en) | 2019-05-08 | 2021-12-30 | Vimalan Biosciences Inc | Jak inhibitors |
CN110305140B (zh) * | 2019-07-30 | 2020-08-04 | 上海勋和医药科技有限公司 | 二氢吡咯并嘧啶类选择性jak2抑制剂 |
WO2021026465A1 (en) | 2019-08-08 | 2021-02-11 | Vimalan Biosciences, Inc. | Jak inhibitors |
GB201911868D0 (en) * | 2019-08-19 | 2019-10-02 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
EP4027993A4 (en) * | 2019-09-13 | 2023-09-20 | The Broad Institute Inc. | CYCLOOXYGENASE INHIBITORS AND USES THEREOF |
GB201914910D0 (en) * | 2019-10-15 | 2019-11-27 | Sentinel Oncology Ltd | Pharmaceutical compounds |
CN117043163A (zh) * | 2021-09-08 | 2023-11-10 | 希格生科(深圳)有限公司 | 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途 |
CN114957248B (zh) * | 2022-05-09 | 2023-12-29 | 南开大学 | 一种吡咯并嘧啶化合物及其制备方法、药物组合物和应用 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7917643B2 (en) * | 1996-09-12 | 2011-03-29 | Audible, Inc. | Digital information library and delivery system |
US20030074530A1 (en) * | 1997-12-11 | 2003-04-17 | Rupaka Mahalingaiah | Load/store unit with fast memory data access mechanism |
US6887224B2 (en) * | 1998-06-15 | 2005-05-03 | Ilse Rubio | Close fitting leakage resistant feminine hygiene pad |
EA005852B1 (ru) | 1998-06-19 | 2005-06-30 | Пфайзер Продактс Инк. | ПИРРОЛО[2,3-d]ПИРИМИДИНЫ |
CN1195755C (zh) | 1999-12-10 | 2005-04-06 | 辉瑞产品公司 | 吡咯并[2,3-d]嘧啶化合物 |
WO2002076985A1 (en) * | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
KR100714519B1 (ko) | 2002-03-07 | 2007-05-07 | 에프. 호프만-라 로슈 아게 | 이환 피리딘 및 피리미딘 p38 키나아제 억제제 |
US7132221B2 (en) * | 2003-09-12 | 2006-11-07 | Headway Technologies, Inc. | Method to print photoresist lines with negative sidewalls |
US7532909B2 (en) * | 2003-10-15 | 2009-05-12 | Nextel Communications Inc. | System and method for providing dedicated paging channels for walkie-talkie services |
US7319102B1 (en) | 2003-12-09 | 2008-01-15 | The Procter & Gamble Company | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors |
BRPI0507668A (pt) * | 2004-02-14 | 2007-07-17 | Irm Llc | compostos e composições como inibidores de proteìna cinase |
RU2006135120A (ru) | 2004-03-05 | 2008-04-10 | Тайсо Фармасьютикал Ко. | Производные пирролопиримидина |
WO2005107760A1 (en) * | 2004-04-30 | 2005-11-17 | Irm Llc | Compounds and compositions as inducers of keratinocyte differentiation |
JP5118972B2 (ja) * | 2004-10-29 | 2013-01-16 | テイボテク・フアーマシユーチカルズ | Hiv阻害性二環式ピリミジン誘導体 |
US20060122003A1 (en) * | 2004-12-03 | 2006-06-08 | Kim Jong H | Portable golf swing position training aid kit |
ES2411975T3 (es) | 2005-01-14 | 2013-07-09 | Janssen Pharmaceutica Nv | Pirimidinas heterocíclicas anilladas de 5 miembros como inhibidores de cinasas |
US8633205B2 (en) * | 2005-02-03 | 2014-01-21 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein kinases |
JP2006241089A (ja) | 2005-03-04 | 2006-09-14 | Astellas Pharma Inc | ピロロピリミジン誘導体またはその塩 |
ATE541848T1 (de) | 2005-05-05 | 2012-02-15 | Ardea Biosciences Inc | Diaryl-purin, azapurine und deazapurine als nichtnukleoside reverse-transkriptase-inhibitoren zur behandlung von hiv |
US7749527B2 (en) | 2005-05-24 | 2010-07-06 | Wyeth Llc | Gel compositions for control of ecto-parasites |
EA200800664A1 (ru) | 2005-10-13 | 2009-02-27 | Глаксо Груп Лимитед | Производные пирролопиримидина в качестве ингибиторов syk |
EP2385053B1 (en) | 2005-11-17 | 2013-10-02 | OSI Pharmaceuticals, Inc. | Intermediates for the preparation of fused bicyclic mTOR inhibitors |
PT3184526T (pt) | 2005-12-13 | 2018-12-19 | Incyte Holdings Corp | Derivados de pirrolo[2,3-d]pirimidina como inibidores da cinase janus |
EP2001476A4 (en) | 2006-03-20 | 2010-12-22 | Synta Pharmaceuticals Corp | BENZOIMIDAZOLYL-PARAZINE-BASED COMPOUNDS FOR INFLAMMATION USES AND IMMUNE DISORDERS |
TWI398252B (zh) | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
JP4861772B2 (ja) * | 2006-08-28 | 2012-01-25 | 富士通株式会社 | 移動体標定プログラム、該プログラムを記録した記録媒体、移動体標定装置、および移動体標定方法 |
CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
KR20090033605A (ko) * | 2007-10-01 | 2009-04-06 | 삼성전자주식회사 | 적층형 반도체 패키지, 그 형성방법 및 이를 구비하는전자장치 |
US20090149458A1 (en) | 2007-11-27 | 2009-06-11 | Wyeth | PYRROLO[3,2-d]PYRIMIDINE COMPOUNDS AND THEIR USE AS PI3 KINASE AND mTOR KINASE INHIBITORS |
WO2009085185A1 (en) | 2007-12-19 | 2009-07-09 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
US20090192176A1 (en) | 2008-01-30 | 2009-07-30 | Wyeth | 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES |
-
2009
- 2009-02-04 EP EP09708802A patent/EP2247591A1/en not_active Withdrawn
- 2009-02-04 NZ NZ587271A patent/NZ587271A/en not_active IP Right Cessation
- 2009-02-04 KR KR1020107019690A patent/KR101277823B1/ko not_active IP Right Cessation
- 2009-02-04 WO PCT/EP2009/051281 patent/WO2009098236A1/en active Application Filing
- 2009-02-04 JP JP2010545458A patent/JP5323095B2/ja not_active Expired - Fee Related
- 2009-02-04 BR BRPI0908433A patent/BRPI0908433A2/pt not_active IP Right Cessation
- 2009-02-04 KR KR1020137011455A patent/KR20130066703A/ko not_active Application Discontinuation
- 2009-02-04 CA CA2714177A patent/CA2714177A1/en not_active Abandoned
- 2009-02-04 UY UY031631A patent/UY31631A1/es not_active Application Discontinuation
- 2009-02-04 PE PE2009000162A patent/PE20091485A1/es not_active Application Discontinuation
- 2009-02-04 CN CN2009801117630A patent/CN101981036B/zh not_active Expired - Fee Related
- 2009-02-04 AR ARP090100362A patent/AR070558A1/es not_active Application Discontinuation
- 2009-02-04 AU AU2009211338A patent/AU2009211338B2/en not_active Ceased
- 2009-02-04 MX MX2010008719A patent/MX2010008719A/es active IP Right Grant
- 2009-02-04 EA EA201001242A patent/EA017952B1/ru not_active IP Right Cessation
- 2009-02-05 TW TW098103755A patent/TW200938202A/zh unknown
- 2009-02-05 US US12/366,218 patent/US8420657B2/en not_active Expired - Fee Related
- 2009-02-05 PA PA20098815201A patent/PA8815201A1/es unknown
- 2009-02-05 CL CL2009000255A patent/CL2009000255A1/es unknown
-
2010
- 2010-07-26 IL IL207224A patent/IL207224A0/en unknown
- 2010-07-27 ZA ZA2010/05338A patent/ZA201005338B/en unknown
- 2010-07-29 CR CR11614A patent/CR11614A/es not_active Application Discontinuation
- 2010-08-04 NI NI201000137A patent/NI201000137A/es unknown
- 2010-08-04 DO DO2010000242A patent/DOP2010000242A/es unknown
- 2010-09-02 MA MA33139A patent/MA32134B1/fr unknown
- 2010-09-02 SM SM201000104T patent/SMP201000104B/it unknown
- 2010-09-06 EC EC2010010463A patent/ECSP10010463A/es unknown
- 2010-09-06 CO CO10110021A patent/CO6321262A2/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0908433A2 (pt) | pirrolo[2,3-d]piridinas e empregos destas como inibidores tirosina cinase | |
LTPA2020504I1 (lt) | Pakeistieji pirazolo[1,5-a]pirimidino junginiai kaip Trk kinazės slopikliai | |
BRPI0809998A2 (pt) | Composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina cinase | |
CU23886B1 (es) | Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteínas quinasas b | |
PL2252597T3 (pl) | Pochodne pirazyny i ich zastosowanie jako inhibitorów kinaz białkowych | |
BRPI1011066A2 (pt) | "pirazolopirimidinas e heterociclos relacionados como inibidores de quinase | |
IL211549A0 (en) | Aminotriazolopyridines and their use as kinase inhibitors | |
BRPI0922095A2 (pt) | derivados de piridina e pirimidina como inibidores de fosfodiesterase 10 | |
SMT201400123B (it) | Imidazo[1,2B]piridazine sostituite come inibitori di trk-chinasi | |
BRPI0820544A2 (pt) | 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase | |
BRPI0913580A2 (pt) | pirrolopiridinas como inibidores de quinase | |
BRPI0921598A2 (pt) | derivados de piridina e pirimidina como inibidores de fosfodiesterase 10 | |
BRPI0916295A2 (pt) | inibidores de pirazolopiridina tricíclica cinase | |
BR112012007300A2 (pt) | derivador de pirimidina como inibidores proteína tirosina cinase 2 | |
BRPI1012108A2 (pt) | 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- ou heptano-nitrila como inibidores de jak | |
BRPI0807893A2 (pt) | Imidazoquinolinas como inibidores duais de lipídio quinase e mtor. | |
PL2419428T3 (pl) | Pochodne imidazo[1,2-A]pirydyny jako inhibitory kinaz FGFR do zastosowania w terapii | |
DK2384326T3 (da) | Pyrrolo[2,3-d]pyrimidinforbindelser | |
BRPI0920135A2 (pt) | imidazopiridazinacarbonitrilos úteis como inibidores de quinase | |
BRPI0913879A2 (pt) | fenilpirazinonas como inibidores de quinase | |
IL219424A0 (en) | IMIDAZO [1,2-b] PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | |
ATE522535T1 (de) | Pyrrolotriazin-kinasehemmer | |
BRPI0813831A2 (pt) | Compostos de heteroarila bicíclica e seu uso como inibidores de quinase | |
BR112012002110A2 (pt) | derivados de pirrolo[1,2-b]piridazina como inibidores de janus cinase | |
ZA201105896B (en) | [1,2,4] triazolo [1,5-a] pyridines as kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |